An interventional study of MCOK-01 in Myopia and Myopic Astigmatism, sponsored by Menicon Co., Ltd.. Not yet recruiting at 4 sites in Australia. Open to participants aged 6 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Myopia with a site in Australia — 2 open to participants now, 4 under way, none of them phase 3. Myopia · Australia.
Among the 14 studies in Myopia with a site in Australia, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, and was the 14th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →2 of the 14 studies in Myopia with a site in Australia are open now. Recruiting first, the newest first:
The University of New South Wales · Sites in Australia, United States
Ages 4–14
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 60 across the 11 interventional studies, 230 across the 1 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 8 most frequent:
Menicon Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Menicon Co., Ltd. has 4 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
1 of the studies in Myopia with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07047924Menicon Co., Ltd.A Clinical Trial Assessing the Safety and Effectiveness of Orthokeratology Lenses in Patients With Myopia and Myopic Astigmatism | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Myopia with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, multi-centre, single-arm clinical trial to evaluate the effectiveness and safety of MCOK-01 lenses in patients with myopia and myopic astigmatism who need dioptric correction.
A maximum number of 220 participants are planned to be enrolled , with a minimum of 150 planned to complete the trial (30% dropout). All participants will be enrolled in Australia.
Enrolled participants will wear the lenses every night for up to 12 months, removing them upon waking. 8 follow up visits will be completed during treatment, after: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of wearing the lenses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be enrolled in the Investigational arm, and treated with the investigational product.
Device: MCOK-01
The investigational device is a Rigid Gas Permeable contact lenses for orthokeratology. MCOK-01 applied the reverse geometry design and adopted the lens material which possesses the highest oxygen permeability among all the materials for orthokeratology lens.
Lines of improvement of monocular uncorrected distance visual acuity
Reading of a logMAR chart. Each line difference represents 0.1 logMAR acuity. The improvement in acuity is represented by a numerical reduction in the logMAR value.
Time frame: 12-months following enrolment
Proportion of eyes achieved uncorrected distance visual acuity of ≤0.30 logMAR, ≤0.20 logMAR, ≤0.10 logMAR, and ≤0.00 logMAR
Measured using a logMAR chart. Each line difference represents 0.1 logMAR acuity. The improvement in acuity is represented by a numerical reduction in the logMAR value.
Time frame: 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
A level of attempted versus achieved reduction in manifest refractive error
Using a Phoropter/Refractor. Proportion of eyes with manifest sphere within ±0.50 D, ±1.00 D, and ±2.00 D of the target (plano)
Time frame: 12 months following enrolment
Number and rates (by type of event and relation to device) of serious and significant adverse events
Adverse events will be self-reported by participants to investigative team
Time frame: Any time within the 12-months enrolment window
Number and rates (by type of event) of all types of adverse events that were not classified as serious or significant adverse events.
Adverse events will be self-reported by participants to investigative team
Time frame: Any time within the 12-months enrolment window
Number of slit lamp results above grade 2
Assessed using a slit lamp
Time frame: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Number and rate of cases of loss of; monocular best spectacle corrected visual acuity (BSCVA) of 2 or more lines (≥ 0.2 logMar), and 1 or more lines (≥ 0.1 logMar).
Assessed with a logMAR chart
Time frame: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Improvement of monocular uncorrected distance visual acuity
Assessed with a logMAR chart. Endpoint will be measured by a set of descriptive statistics.
Time frame: 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Change in best corrected spectacle visual acuity
Assessed using a logMAR chart
Time frame: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Changes in manifest sphere
Measured with a subjective refraction test
Time frame: 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
A level of attempted versus achieved reduction in manifest refractive error
Measured with a subjective refraction test. Proportion of eyes with manifest sphere within ±0.50 D, ±1.00 D, and ±2.00 D of the target (plano)
Time frame: 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Corneal topography changes
Measured with a corneal topographer
Time frame: 12 months following enrolment
Change in absolute corneal astigmatism
Measured with a corneal topographer
Time frame: 12 months following enrolment
Number of discontinued participants and the reasons for discontinuation
Ongoing participation rates will be continuously monitored
Time frame: Any time within the 12-months enrolment window
Number and rates of average wear time per day
Patient reported at scheduled study visits
Time frame: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Increase in corneal or refractive astigmatism of 2D or more and 1D or more post-treatment
Measured with a subjective refraction test
Time frame: 12 months following enrolment
Signs/symptoms and complications from subjective questionnaires
Assessed by the subjective questionnaires completed by participants
Time frame: 1 month, 6 months, and 12 months following enrolment
Descriptive statistics of intraocular pressure (IOP) and for percent change from baseline
Measured using a tonometer
Time frame: 6 months and 12 months following enrolment
Descriptive statistics of specular microscopy measurements
Measured using a specular microscope. Specific parameters include Endothelial Cell Morphology (Cell density (cells/mm2), Polymegethism (CV) and Pleomorphism (percentage of hexagonal cells))
Time frame: 12 months following enrolment
Descriptive statistics of central corneal thickness
Measured using a specular microscope.
Time frame: 6 months, and 12 months following enrolment
Frequency and reasons for lens replacement
Patient reported at scheduled study visits
Time frame: Any time within the 12-months enrolment window
Damage or scratches on the lenses
Time frame: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months following enrolment
Stability in manifest refractive error
Measured with a subjective refraction test. Proportion of eyes with manifest sphere change within ±0.50 D between 1-month and 3-month visit.
Time frame: 1 month and 3 months following enrolment
Stability in unaided visual acuity
Measured using a logMAR chart. Proportion of eyes with unaided visual acuity change within 1 line (0.1 logMAR) between 1-month and 3-month visit.
Time frame: 1 month and 3 months following enrolment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 17 months is above that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Menicon Co., Ltd.